TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05100251
Drug: WBC100 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first stage: single dose escalation according to classic 3+3 dose escalation method. 4 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for 2 consecutive weeks, followed by a 1-week rest period, with 3 weeks as one treatment cycle; The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type
Study: NCT04909164
Drug: Immunnotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.
Study: NCT06560112
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivgtt
Study: NCT05161780
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
Study: NCT04185402
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
Study: NCT05979051
Drug: SHR-1703 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1703 Placebo will be administered by Subcutaneous injection in Phase 3.
Study: NCT06116240
Drug: TQB2450 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
Study: NCT06116240
Drug: AL2846 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL2846 is a multi-targeted tyrosine kinase receptor inhibitor
Study: NCT04872790
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT05831345
Drug: Sufentanil Citrate
Normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
Study: NCT05251948
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is administered orally twice daily on Days 1-14 of each 21 day cycle. Treatment for up to six cycles.
Study: NCT05315999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
Study: NCT05393193
Drug: DTG/ABC/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
Study: NCT05874544
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT06160479
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different amount of calcium supplement in pregnancy
Study: NCT05495295
Drug: PhOx430
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standard 3 + 3 design will be followed. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.~A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval.
Study: NCT05495295
Drug: PhOx430
Approvals — FDA: no, EMA: no, PMDA: no
Description: The implementation of this cohort (Step 3) was decided by the Protocol Steering Committee (PSC) based on clinical and pharmacokinetic data obtained in Steps 1 and 2. Six patients will be enrolled, who will receive PhOx430 orally thrice a day (tid) at a -6-hour interval over 12 hours for 21 days, and then, starting from day 22, four times a day (qid) at a 4-hour interval over 12 hours, continuously in cycles of 21 days. PhOx430 will be taken in single doses of 1,200 mg to patients weighing ≥ 50 kg and of 600 mg to patients weighing \< 50 kg, with no requirement for a full or empty stomach. The first patient will be observed after treatment start for at least 21 days before enrolling the following two. After the third patient is observed for 21 days after treatment start, 3 additional patients will be enrolled without waiting time between them. If the daily dose tested with the tid schedule is not deemed safe, the flat dose will be tested twice a day (bid) at a 12-hour interval.
Study: NCT05381597
Drug: Combination cream of 5-fluorouracil and calcipotriene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply the cream to the size of the lesion extending to the 0.5 cm area of skin surrounding the lesion.twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
Study: NCT05067998
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
Study: NCT04426968
Drug: Hepalatide 2.1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.1 mg/day subcutaneously (s.c.) for 24 week
Study: NCT04426968
Drug: Hepalatide 6.3mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.3mg/day subcutaneously (s.c.) for 24 week
Study: NCT04426968
Drug: placebo 2.1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.1 mg/day subcutaneously (s.c.) for 24 week
Study: NCT04426968
Drug: placebo 4.2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2 mg/day subcutaneously (s.c.) for 24 week
Study: NCT04426968
Drug: placebo 6.3mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.3 mg/day subcutaneously (s.c.) for 24 week
Study: NCT03897075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
Study: NCT05664763
Drug: [18F]FPEB with PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: radioactive tracer \[18F\]FPEB administered by bolus infusion over up to 2 hours with PET performed in the last 30 minutes of infusion with Positron emission tomography (PET) neuroimaging
Study: NCT06800274
Drug: NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 patients were randomly assigned to NAAGA in single dose (49 mg/mL), instilled as 1 drop per eye four times daily for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
Study: NCT06206291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo twice daily for first 4 weeks
Study: NCT05858515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05456360
Drug: Sleep enhancement intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a medication administration will be limited to before bedtime.
Study: NCT06021197
Drug: Placebo Cap
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo as a comparator
Study: NCT05857384
Drug: IHL42X
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHL-42X consists of acetazolamide and dronabinol.
Study: NCT06461429
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Study: NCT06461429
Drug: Amoxicillin and Erythromycin
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Study: NCT06461429
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Study: NCT06461429
Drug: Caffeine citrate: Low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Study: NCT06461429
Drug: Caffeine citrate: Medium dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Study: NCT06461429
Drug: Caffeine citrate: High dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Study: NCT06091267
Drug: Decitabine and cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles.
Study: NCT06091267
Drug: only Decitabine and cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles, until disease progression, unacceptable toxicity, or the subject/investigator decides that the subject should discontinue treatment or withdraw from the trial.
Study: NCT06119581
Drug: LY3537982
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06119581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03651349
Drug: HK-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.
Study: NCT03651349
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
Study: NCT06434064
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05579899
Drug: EVO101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cream
Study: NCT05623982
Drug: GNC-038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT04609904
Drug: BGF MDI 320/28.8/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
Study: NCT04609904
Drug: BGF MDI 320/14.4/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
Study: NCT04609904
Drug: BFF MDI 320/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and formoterol fumarate metered dose inhaler
Study: NCT04609904
Drug: BFF pMDI 320/9 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol fumarate pressurized metered dose inhaler
Study: NCT06179407
Drug: MK-6552
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
Study: NCT06179407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
Study: NCT06455059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of recommended dose of placebo
Study: NCT05096234
Drug: [ 18F]F-AraG PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
Study: NCT06355583
Drug: EBX-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBX-102 is a white size 0 gastro-resistant hydroxypropyl methylcellulose (HPMC) capsule containing communities of dried, intestinal microorganisms extracted from rigorously screened pooled human stool samples obtained from volunteer accredited donors.
Study: NCT06111547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.
Study: NCT06355583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The capsules contain inactive ingredients microcrystalline cellulose and magnesium stearate.
Study: NCT06604624
Drug: HD1916
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
Study: NCT06177457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as tablets; QD over 14 days
Study: NCT06544707
Drug: 0.003% AR-15512
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution administered via topical ocular instillation
Study: NCT06317636
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline infused intravenously over 40 minutes
Study: NCT06321341
Drug: Vespireit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone
Study: NCT06321341
Drug: Arlevert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate + Cinnarizine
Study: NCT05879055
Drug: PM8002
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06331845
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle
Study: NCT06798675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06561685
Drug: LY4050784
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05012735
Drug: Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
Study: NCT06799442
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mic fentanylwhich is also diluted to 2 ml.
Study: NCT06032546
Drug: Placebo for ABBV-382
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT06382155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized powder for reconstitution
Study: NCT05820685
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will get acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, gabapentin 300 mg every eight hours, and Tramadol 50 mg every six hours as needed for breakthrough pain
Study: NCT06249191
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05327556
Drug: Epinephrine 0.5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe with 5 mcg/mL epinephrine
Study: NCT05327556
Drug: Epinephrine 1 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe with 10 mcg/mL epinephrine
Study: NCT06677307
Drug: KRRO-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRRO-110 drug product, IV
Study: NCT05754073
Drug: 2. Intranasal placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 IU, twice daily for 12 months in the placebo comparator arm in double-blinded phase
Study: NCT05700448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05463432
Drug: HR19024
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05757596
Drug: VSA001 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.
Study: NCT05757596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Saline, volume matched
Study: NCT05931484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of Placebo
Study: NCT05130866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo orally 3 times per week for 3 weeks followed by 1 week off for a 4-week cycle.
Study: NCT05504265
Drug: Preemptive flurbiprofen axetil
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg once，30min before induction anesthesia
Study: NCT05504265
Drug: Postoperative flurbiprofen axetil
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg bid
Study: NCT06492512
Drug: daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill daily
Study: NCT06492512
Drug: alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill every other day
Study: NCT04049331
Drug: Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: first two doses four weeks apart; following three more doses every ten weeks.
Study: NCT05910827
Drug: HMBD-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
Study: NCT06045936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection
Study: NCT04806451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active dosage form
Study: NCT06516510
Drug: lutetium (177Lu) rhPSMA 10.1 and Pluvicto®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopharmaceutical
Study: NCT06434909
Drug: Cytalux™ (pafolacianine) for fluorescent imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytalux™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye for real-time cancer margin status.~This is used in conjunction with appropriate imaging system.
Study: NCT04822961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senaparib-matched placebo capsules
Study: NCT06801119
Drug: HN2301 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.
Study: NCT05876598
Drug: antibiotic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The outcome of the study will be to implement Prediction Models to support clinicians for the assessment of risk of having a bloodstream infection.
Study: NCT06484855
Drug: IBI355
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI355 IV. Q4W
Study: NCT06484855
Drug: IBI355 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI355 placebo IV. Q4W
Study: NCT06381986
Drug: SHJ002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic
Study: NCT06793488
Drug: Disulfiram 250 mg
Normalized name: disulfiram 250 MG
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram will be used in Participants with Alcohol Use Disorder only to facilitate abstinence.
Study: NCT06654726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05303090
Drug: H101
Normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Approvals — FDA: no, EMA: no, PMDA: no
Description: H101 intratumorally injection starts at day 0.
Study: NCT06242028
Drug: Group P
Normalized name: High mobility group protein HMGI-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine and 4 mg dexamethasone.
Study: NCT06242028
Drug: Group S
Normalized name: Blood group substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine. In addition, 4 mg dexamethasone will be administered intravenously.
Study: NCT06800612
Drug: Oncologic drug administered for treatment of gynecologic cancer
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded
Study: NCT05958407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a loading dose under the skin (s.c.) at baseline, trial participants are administered a placebo dose every two weeks for 16 weeks
Study: NCT05664477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.